About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker LKFT · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Jul 13, 2026Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell T…
NCT06652633 · Hematological Malignancies
GLPG CAR T-cell therapy
LKFT
Lakefront Biotherapeutics NV
Phase 3Recruiting546Jul 2039Registry ↗
Jun 30, 2026A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Ly…
NCT06561425 · Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas…
GLPG5101
LKFT
Lakefront Biotherapeutics NV
Phase 1/2Terminated130May 27, 2026Registry ↗
May 14, 2026A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants Wit…
NCT05856448 · Systemic Lupus Erythematosus
GLPG3667, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed186Oct 8, 2025Registry ↗
May 14, 2026A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults Wit…
NCT05695950 · Dermatomyositis
GLPG3667, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed40Oct 13, 2025Registry ↗
Oct 9, 2024Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Ac…
NCT03201445 · Inflammatory Bowel Disease
Filgotinib, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated139Nov 20, 2020Registry ↗
Oct 4, 2024A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Coli…
NCT05479058 · Ulcerative Colitis
Filgotinib, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 3Terminated22Oct 9, 2023Registry ↗
Sep 19, 2024Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects
NCT05272683 · Healthy
GLPG3667, Itraconazole
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed14Apr 1, 2022Registry ↗
Sep 19, 2024Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects
NCT04971746 · Healthy
Pirfenidone, GLPG4716
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed58May 9, 2022Registry ↗
Sep 19, 2024A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are…
NCT04856358 · Healthy
GLPG3121, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed50Nov 8, 2021Registry ↗
Sep 19, 2024Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects
NCT04720183 · Healthy
Sulfasalazine, GLPG3970
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed8Apr 21, 2021Registry ↗
Sep 19, 2024A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
NCT04106297 · Healthy, Psoriasis
GLPG3970 oral solution, Placebo oral solution
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed100Mar 5, 2021Registry ↗
Sep 19, 2024A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667
NCT04097938 · Healthy
GLPG3667 oral suspension, Placebos
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed52Mar 4, 2020Registry ↗
Aug 22, 2024A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidn…
NCT04578548 · Autosomal Dominant Polycystic Kidney Disease
GLPG2737, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated66Dec 14, 2022Registry ↗
Jul 10, 2024Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
NCT02914600 · Crohn's Disease
Filgotinib, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 3Terminated1,188Aug 1, 2023Registry ↗
Jun 4, 2024Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
NCT02065700 · Rheumatoid Arthritis
Filgotinib
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed739Jan 19, 2023Registry ↗
Apr 30, 2024Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoi…
NCT03926195 · Rheumatoid Arthritis, Psoriatic Arthritis
Filgotinib, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed109Aug 14, 2020Registry ↗
Mar 1, 2024First-in-Human Single Ascending Dose of GLPG0492
NCT01130818 · Healthy
GLPG0492, placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed28Aug 2010Registry ↗
Dec 18, 2023Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Acti…
NCT02914561 · Crohn's Disease
Filgotinib, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 3Completed1,372Nov 11, 2022Registry ↗
Nov 29, 2023Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotini…
NCT06043739 · Bioavailability
Filgotinib, Filgotinib
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed12Oct 27, 2023Registry ↗
Sep 18, 2023A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With A…
NCT04700280 · Primary Sjögren Syndrome
GLPG3970, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated31Oct 28, 2021Registry ↗
Jan 27, 2023A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ul…
NCT04577794 · Ulcerative Colitis
GLPG3970, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed31May 17, 2021Registry ↗
Jul 29, 2022A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmon…
NCT03733444 · Idiopathic Pulmonary Fibrosis
GLPG1690, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 3Terminated781Mar 30, 2021Registry ↗
Jul 29, 2022A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary…
NCT03711162 · Idiopathic Pulmonary Fibrosis
GLPG1690, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 3Terminated525Mar 30, 2021Registry ↗
Jul 18, 2022A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Mo…
NCT04577781 · Rheumatoid Arthritis
GLPG3970, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed28Mar 26, 2021Registry ↗
Jun 30, 2022Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667
NCT05335447 · Healthy
GLPG3667 capsule, [14C]-GLPG3667 solution for infusion
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed5Jun 3, 2022Registry ↗
Apr 21, 2022An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
NCT03320876 · Psoriatic Arthritis
filgotinib
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated122Jun 30, 2021Registry ↗
Mar 29, 2022A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
NCT03976648 · Systemic Sclerosis
GLPG1690
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated31Apr 13, 2021Registry ↗
Feb 14, 2022A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult…
NCT04976270 · Healthy
GLPG3667, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed23Jan 14, 2022Registry ↗
Feb 1, 2022A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult…
NCT04653467 · Healthy
GLPG4399 oral suspension, GLPG4399 capsules
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed88Jan 10, 2022Registry ↗
Nov 24, 2021Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
NCT05030857 · Healthy
GLPG4716, Midazolam
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed19Nov 13, 2021Registry ↗
Oct 21, 2021A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Syst…
NCT04700267 · Systemic Lupus Erythematosus
GLPG3970 film-coated tablet, Placebo film-coated tablet
LKFT
Lakefront Biotherapeutics NV
Phase 1Terminated11Oct 6, 2021Registry ↗
Sep 14, 2021A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmon…
NCT03725852 · Idiopathic Pulmonary Fibrosis
GLPG1205, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed68Jul 21, 2020Registry ↗
Jul 28, 2021A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis
NCT03595618 · Osteoarthritis
GLPG1972, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed932Jul 14, 2020Registry ↗
Jul 23, 2021Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970
NCT04907149 · Healthy
GLPG3970 film-coated tablet, [14C]GLPG3970 solution for inf…
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed6Jul 12, 2021Registry ↗
May 27, 2021A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Mo…
NCT04594928 · Plaque Psoriasis
GLPG3667, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed30May 4, 2021Registry ↗
May 11, 2021A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single D…
NCT04575818 · Healthy
GLPG4059 oral suspension, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Terminated32Apr 8, 2021Registry ↗
May 4, 2021A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
NCT03798366 · Systemic Sclerosis
GLPG1690, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed33May 21, 2020Registry ↗
Mar 25, 2021A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation o…
NCT04708184 · Healthy
GLPG3970 oral solution, GLPG3970 tablet
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed12Feb 25, 2021Registry ↗
Mar 25, 2021Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205
NCT04704739 · Healthy
GLPG1205 film-coated tablets, [14C]-GLPG1205 solution for i…
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed12Mar 2, 2021Registry ↗
Mar 3, 2021Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects
NCT04736927 · Healthy
GLPG3667, Midazolam
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed14Feb 25, 2021Registry ↗
Jan 5, 2021A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical C…
NCT03864627 · Atopic Dermatitis
MOR106, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated33Feb 27, 2020Registry ↗
Dec 22, 2020A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese…
NCT04532567 · Healthy
GLPG1205, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed32Dec 10, 2020Registry ↗
Dec 16, 2020Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DAR…
NCT01894516 · Rheumatoid Arthritis
GLPG0634, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed287Mar 5, 2015Registry ↗
Nov 17, 2020Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participant…
NCT01888874 · Rheumatoid Arthritis
GLPG0634, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed599Feb 18, 2015Registry ↗
Nov 6, 2020Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in…
NCT02738801 · Idiopathic Pulmonary Fibrosis
GLPG1690 600 mg QD, Placebo QD
LKFT
Lakefront Biotherapeutics NV
Phase 2Completed23May 2, 2017Registry ↗
Mar 19, 2020A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatme…
NCT03800472 · Healthy
GLPG3312 IR, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed95Mar 10, 2020Registry ↗
Mar 18, 2020A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a…
NCT03689829 · Healthy, Atopic Dermatitis
MOR106, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 1Terminated44Mar 2, 2020Registry ↗
Mar 18, 2020A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of…
NCT03568071 · Atopic Dermatitis
MOR 106, Placebo
LKFT
Lakefront Biotherapeutics NV
Phase 2Terminated207Mar 3, 2020Registry ↗
Jan 13, 2020A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG19…
NCT04137341 · Healthy
GLPG1972 - A, GLPG1972 - B
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed18Dec 13, 2019Registry ↗
Nov 20, 2019A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body W…
NCT04136327 · Healthy
GLPG1972 film-coated tablets, [14C]-GLPG1972 solution for i…
LKFT
Lakefront Biotherapeutics NV
Phase 1Completed6Oct 21, 2019Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:10 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances